scholarly journals Cardiac metabolism — A promising therapeutic target for heart failure

2018 ◽  
Vol 182 ◽  
pp. 95-114 ◽  
Author(s):  
Hannah Noordali ◽  
Brodie L. Loudon ◽  
Michael P. Frenneaux ◽  
Melanie Madhani
Heart ◽  
1997 ◽  
Vol 77 (2) ◽  
pp. 93-94 ◽  
Author(s):  
M. P. Love ◽  
J. J. McMurray

Cells ◽  
2019 ◽  
Vol 8 (12) ◽  
pp. 1558 ◽  
Author(s):  
Iman Abdelaziz Mohamed ◽  
Alain-Pierre Gadeau ◽  
Anwarul Hasan ◽  
Nabeel Abdulrahman ◽  
Fatima Mraiche

Osteopontin (OPN) is recognized for its significant roles in both physiological and pathological processes. Initially, OPN was recognized as a cytokine with pro-inflammatory actions. More recently, OPN has emerged as a matricellular protein of the extracellular matrix (ECM). OPN is also known to be a substrate for proteolytic cleavage by several proteases that form an integral part of the ECM. In the adult heart under physiological conditions, basal levels of OPN are expressed. Increased expression of OPN has been correlated with the progression of cardiac remodeling and fibrosis to heart failure and the severity of the condition. The intricate process by which OPN mediates its effects include the coordination of intracellular signals necessary for the differentiation of fibroblasts into myofibroblasts, promoting angiogenesis, wound healing, and tissue regeneration. In this review, we discuss the role of OPN in contributing to the development of cardiac fibrosis and its suitability as a therapeutic target.


Author(s):  
Zheng Ma ◽  
Juan-Juan Song ◽  
Sara Martin ◽  
Xin-Chun Yang ◽  
Jiu-Chang Zhong

2019 ◽  
Author(s):  
Silvia Scaricamazza ◽  
Illari Salvatori ◽  
Giacomo Giacovazzo ◽  
Jean Philippe Loeffler ◽  
Frederique Renè ◽  
...  

2021 ◽  
Vol 22 (8) ◽  
pp. 4110
Author(s):  
Gerhild Euler ◽  
Jens Kockskämper ◽  
Rainer Schulz ◽  
Mariana S. Parahuleva

Heart failure (HF) and atrial fibrillation (AF) are two major life-threatening diseases worldwide. Causes and mechanisms are incompletely understood, yet current therapies are unable to stop disease progression. In this review, we focus on the contribution of the transcriptional modulator, Jun dimerization protein 2 (JDP2), and on HF and AF development. In recent years, JDP2 has been identified as a potential prognostic marker for HF development after myocardial infarction. This close correlation to the disease development suggests that JDP2 may be involved in initiation and progression of HF as well as in cardiac dysfunction. Although no studies have been done in humans yet, studies on genetically modified mice impressively show involvement of JDP2 in HF and AF, making it an interesting therapeutic target.


Sign in / Sign up

Export Citation Format

Share Document